PTAB Won't Revisit Patent For Astellas Bladder Drug
The Patent Trial and Appeal Board on Friday said it wouldn't re-evaluate an Astellas Pharma Inc. patent covering the overactive bladder treatment drug Myrbetriq, despite a push from a unit of...To view the full article, register now.
Already a subscriber? Click here to view full article